About 76% of patients with lung adenocarcinoma harbor activating mutations in the receptor tyrosine kinase (RTK)/RAS/RAF pathways, leading to aberrant activation of the mitogen‐activated protein kinase (MAPK) pathways particularly the MAPK/ERK pathway. This evidence concerns the gene RAF1 and lung adenocarcinoma.